Drugs approved for the treatment of multiple sclerosis: review of their safety profile
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drugs approved for the treatment of multiple sclerosis: review of their safety profile
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 16, Issue 12, Pages 1359-1371
Publisher
Informa UK Limited
Online
2017-10-04
DOI
10.1080/14740338.2017.1388371
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments
- (2017) Gaëlle Clavel et al. JOINT BONE SPINE
- Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
- (2017) Jagannadha Avasarala et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis
- (2017) Usha Ranganathan et al. Multiple Sclerosis Journal
- Liver injury associated with dimethyl fumarate in multiple sclerosis patients
- (2017) Monica A Muñoz et al. Multiple Sclerosis Journal
- Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome
- (2017) Wallace J Brownlee et al. Multiple Sclerosis Journal
- Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis
- (2017) Usha Ranganathan et al. Multiple Sclerosis Journal
- Liver injury associated with dimethyl fumarate in multiple sclerosis patients
- (2017) Monica A Muñoz et al. Multiple Sclerosis Journal
- Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome
- (2017) Wallace J Brownlee et al. Multiple Sclerosis Journal
- Safety concerns and risk management of multiple sclerosis therapies
- (2016) P. Soelberg Sorensen ACTA NEUROLOGICA SCANDINAVICA
- Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
- (2016) Thomas Berger et al. CNS DRUGS
- Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis
- (2016) Maja Živković et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis
- (2016) Mark Obermann et al. Multiple Sclerosis Journal
- Cutaneous adverse events in multiple sclerosis patients treated with daclizumab
- (2016) Irene Cortese et al. NEUROLOGY
- Malignancies after mitoxantrone for multiple sclerosis
- (2016) Mathias Buttmann et al. NEUROLOGY
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Fingolimod-associated PML in a patient with prior immunosuppression
- (2016) Tirisham V. Gyang et al. NEUROLOGY
- Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis
- (2016) Mark Obermann et al. Multiple Sclerosis Journal
- Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis
- (2016) Francesco Antonio Losavio et al. Multiple Sclerosis and Related Disorders
- Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence
- (2016) Bhupendra O. Khatri Therapeutic Advances in Neurological Disorders
- Onset of secondary progressive MS after long-term rituximab therapy - a case report
- (2016) H.-Christian von Büdingen et al. Annals of Clinical and Translational Neurology
- The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
- (2015) Tjalf Ziemssen et al. BMC Neurology
- Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
- (2015) Tobias Ruck et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis
- (2015) Robert Zivadinov et al. JOURNAL OF NEUROIMAGING
- Body weight-based natalizumab treatment in adult patients with multiple sclerosis
- (2015) M. Tanaka et al. JOURNAL OF NEUROLOGY
- Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
- (2015) Erin E Longbrake et al. Multiple Sclerosis Journal
- The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
- (2015) D. M. Hartung et al. NEUROLOGY
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML: The Dark Side of Immunotherapy in Multiple Sclerosis
- (2015) Clemens Warnke et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients
- (2015) Erin E Longbrake et al. Multiple Sclerosis Journal
- Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
- (2015) Eva Havrdova et al. Therapeutic Advances in Neurological Disorders
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
- (2014) Arianna Sartori et al. EXPERT OPINION ON PHARMACOTHERAPY
- Thyroid papillary carcinoma after alemtuzumab therapy for MS
- (2014) Richard Ibitoye et al. JOURNAL OF NEUROLOGY
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Aaron E Miller et al. LANCET NEUROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- The investigation of acute optic neuritis: a review and proposed protocol
- (2014) Axel Petzold et al. Nature Reviews Neurology
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new cases
- (2014) Reza Vosoughi et al. Multiple Sclerosis and Related Disorders
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study
- (2013) Victor M Rivera et al. BMC Neurology
- Natalizumab: A Review of Its Use in the Management of Relapsing-Remitting Multiple Sclerosis
- (2013) Paul L. McCormack DRUGS
- Mitoxantrone-related acute leukemia in MS: An open or closed book?
- (2013) A. Chan et al. NEUROLOGY
- PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
- (2013) Bob W. van Oosten et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient Treated with Fumaric Acid
- (2013) Ummehan Ermis et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
- (2013) Ron Milo Therapeutic Advances in Neurological Disorders
- Teriflunomide in relapsing multiple sclerosis: therapeutic utility
- (2013) Mark S. Freedman Therapeutic Advances in Chronic Disease
- Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies
- (2012) A. Bellizzi et al. JOURNAL OF NEUROVIROLOGY
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Thrombotic microangiopathy and associated renal disorders
- (2012) T. Barbour et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Fingolimod treatment in multiple sclerosis leads to increased macular volume
- (2012) R. Nolan et al. NEUROLOGY
- Higher macular volume in patients with MS receiving fingolimod: Positive outcome or side effect?
- (2012) M. Dinkin et al. NEUROLOGY
- Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod
- (2012) C. M. Gross et al. NEUROLOGY
- Fingolimod-associated macular edema: Incidence, detection, and management
- (2012) N. Jain et al. NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany
- (2012) Anke Stroet et al. Therapeutic Advances in Neurological Disorders
- The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
- (2011) Bernd C. Kieseier CNS DRUGS
- A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy
- (2011) Simone C Wuest et al. NATURE MEDICINE
- Intrathecal effects of daclizumab treatment of multiple sclerosis
- (2011) B. Bielekova et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720)
- (2011) Daniel Ontaneda et al. Expert Review of Clinical Pharmacology
- Interferon-β-1b
- (2010) Greg L. Plosker CNS DRUGS
- PRISMS: the story of a pivotal clinical trial series in multiple sclerosis
- (2010) Bruce A. Cohen et al. CURRENT MEDICAL RESEARCH AND OPINION
- Glatiramer Acetate
- (2010) Natalie J. Carter et al. DRUGS
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
- (2010) Daniel Wynn et al. LANCET NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
- (2009) Eugene O. Major Annual Review of Medicine
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT
- (2009) J. Dorr et al. NEUROLOGY
- Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
- (2008) Bruce D. Trapp et al. Annual Review of Neuroscience
- Interferon-β treatment for relapsing multiple sclerosis
- (2008) Bianca Weinstock-Guttman et al. EXPERT OPINION ON BIOLOGICAL THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now